焦磷酸测序检测呼吸道标本中烟曲霉cyp51A介导的三唑类耐药
研究开发并验证了焦磷酸测序技术,用于从临床呼吸道标本和烟曲霉分离株中检测与耐药相关的cyp51A多态性。对50株烟曲霉分离株验证后,应用于160例患者的326份烟曲霉qPCR阳性呼吸道标本,发现焦磷酸测序可检出培养阴性的耐药基因型,且比培养更早发现耐药。
要点
- 焦磷酸测序可检测与三唑类耐药相关的cyp51A多态性,包括商业检测未覆盖的突变。
- 在培养阴性的qPCR阳性标本中,焦磷酸测序仍可检出耐药基因型。
- 焦磷酸测序比传统培养更早发现耐药,有助于及时调整抗真菌治疗。
核心结论
- 焦磷酸测序法可检测与三唑类耐药相关的多种cyp51A多态性,包括商业检测未覆盖的突变。
- 该方法能在培养阴性时及时识别耐药并指导选择适当的抗真菌治疗。
研究设计与样本
- 方法验证:对50株具有不同三唑类敏感性模式的烟曲霉分离株进行Sanger测序和焦磷酸测序。
- 临床应用:对2017年1月至2019年3月27个月期间英国国家曲霉病中心160例患者的326份烟曲霉qPCR阳性呼吸道标本进行cyp51A焦磷酸测序。
- 比较对象:将Sanger测序和焦磷酸测序结果与高容量培养和标准药敏试验结果进行比较。
主要发现
- 50株分离株的cyp51A基因型经焦磷酸测序和Sanger测序结果一致。
- 326份烟曲霉qPCR阳性呼吸道标本中,71.2%报告无烟曲霉生长。
- 上述无生长标本中,56.9%(132/232)经焦磷酸测序显示野生型cyp51A基因型,31.5%(73/232)显示耐药基因型。
- 焦磷酸测序在18.7%(61/326)的样本中检出环境相关TR34/L98H突变,而培养仅检出6.4%(21/326)的泛唑类耐药。
- 焦磷酸测序在23.3%的标本中比培养更早检测到耐药。
临床怎么用
- 对于烟曲霉qPCR阳性但培养阴性的呼吸道标本,可采用焦磷酸测序检测cyp51A耐药突变。
- 焦磷酸测序结果有助于早期识别三唑类耐药并指导抗真菌药物选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infections caused by triazole drug-resistant Aspergillus fumigatus are an increasing problem. The sensitivity of standard culture is poor, abrogating susceptibility testing. Early detection of resistance can improve patient outcomes, yet tools for this purpose are limited. OBJECTIVES: To develop and validate a pyrosequencing technique to detect resistance-conferring cyp51A polymorphisms from clinical respiratory specimens and A. fumigatus isolates. METHODS: Method validation was performed by Sanger sequencing and pyrosequencing of 50 A. fumigatus isolates with a spectrum of triazole susceptibility patterns. Then, 326 Aspergillus quantitative PCR (qPCR)-positive respiratory samples collected over a 27 month period (January 2017-March 2019) from 160 patients at the UK National Aspergillosis Centre were assessed by cyp51A pyrosequencing. The Sanger sequencing and pyrosequencing results were compared with those from high-volume culture and standard susceptibility testing. RESULTS: The cyp51A genotypes of the 50 isolates analysed by pyrosequencing and Sanger sequencing matched. Of the 326 Aspergillus qPCR-positive respiratory specimens, 71.2% were reported with no A. fumigatus growth. Of these, 56.9% (132/232) demonstrated a WT cyp51A genotype and 31.5% (73/232) a resistant genotype by pyrosequencing. Pyrosequencing identified the environmental TR34/L98H mutation in 18.7% (61/326) of the samples in contrast to 6.4% (21/326) pan-azole resistance detected by culture. Importantly, pyrosequencing detected resistance earlier than culture in 23.3% of specimens. CONCLUSIONS: The pyrosequencing assay described could detect a wide range of cyp51A polymorphisms associated with triazole resistance, including those not identified by commercial assays. This method allowed prompt recognition of resistance and the selection of appropriate antifungal treatment when culture was negative.
引用
- Novak-Frazer L, Anees-Hill SP, Hassan D, et al. Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. J Antimicrob Chemother. 2020. PMID: 32862231. doi:10.1093/jac/dkaa357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。